Insulin Pump Recall Leads To FDA Warning Letter For Medtronic

The missive reflects quality systems issues at the Northridge, CA headquarters of Medtronic’s diabetes division. Analysts are split on what the warning letter’s long-term impact may be.

Medtronic sign.
• Source: Shutterstock

More from Regulation

More from Policy & Regulation